These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 20523072)

  • 1. FIP1L1/PDGFR alpha-associated systemic mastocytosis.
    Yamada Y; Cancelas JA
    Int Arch Allergy Immunol; 2010; 152 Suppl 1(Suppl 1):101-5. PubMed ID: 20523072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.
    Pardanani A; Ketterling RP; Brockman SR; Flynn HC; Paternoster SF; Shearer BM; Reeder TL; Li CY; Cross NC; Cools J; Gilliland DG; Dewald GW; Tefferi A
    Blood; 2003 Nov; 102(9):3093-6. PubMed ID: 12842979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.
    Florian S; Esterbauer H; Binder T; Müllauer L; Haas OA; Sperr WR; Sillaber C; Valent P
    Leuk Res; 2006 Sep; 30(9):1201-5. PubMed ID: 16406018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities.
    Maric I; Robyn J; Metcalfe DD; Fay MP; Carter M; Wilson T; Fu W; Stoddard J; Scott L; Hartsell M; Kirshenbaum A; Akin C; Nutman TB; Noel P; Klion AD
    J Allergy Clin Immunol; 2007 Sep; 120(3):680-7. PubMed ID: 17628645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ETV6-PDGFRB and FIP1L1-PDGFRA stimulate human hematopoietic progenitor cell proliferation and differentiation into eosinophils: the role of nuclear factor-κB.
    Montano-Almendras CP; Essaghir A; Schoemans H; Varis I; Noël LA; Velghe AI; Latinne D; Knoops L; Demoulin JB
    Haematologica; 2012 Jul; 97(7):1064-72. PubMed ID: 22271894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
    La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C
    Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease.
    Yamada Y; Rothenberg ME; Lee AW; Akei HS; Brandt EB; Williams DA; Cancelas JA
    Blood; 2006 May; 107(10):4071-9. PubMed ID: 16418325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
    Salemi S; Yousefi S; Simon D; Schmid I; Moretti L; Scapozza L; Simon HU
    Allergy; 2009 Jun; 64(6):913-8. PubMed ID: 19210352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study.
    Helbig G; Moskwa A; Hus M; Piszcz J; Swiderska A; Urbanowicz A; Całbecka M; Gajkowska J; Seferyńska I; Hałasz M; Woszczyk D; Markiewicz M; Krzemień S
    Hematol Oncol; 2010 Jun; 28(2):93-7. PubMed ID: 19728396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies.
    Pardanani A; Lim KH; Lasho TL; Finke C; McClure RF; Li CY; Tefferi A
    Blood; 2009 Oct; 114(18):3769-72. PubMed ID: 19713463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells.
    Verstovsek S; Giles FJ; Quintás-Cardama A; Manshouri T; Huynh L; Manley P; Cortes J; Tefferi A; Kantarjian H
    Leuk Res; 2006 Dec; 30(12):1499-505. PubMed ID: 16682077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eosinophilia in mast cell disease.
    Kovalszki A; Weller PF
    Immunol Allergy Clin North Am; 2014 May; 34(2):357-64. PubMed ID: 24745679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase: case report.
    Rodzaj M; Gałazka K; Majewski M; Zduńczyk A
    Pol Arch Med Wewn; 2009 Dec; 119(12):838-41. PubMed ID: 20010473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia.
    Pardanani A; Brockman SR; Paternoster SF; Flynn HC; Ketterling RP; Lasho TL; Ho CL; Li CY; Dewald GW; Tefferi A
    Blood; 2004 Nov; 104(10):3038-45. PubMed ID: 15284118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia.
    Cools J
    Verh K Acad Geneeskd Belg; 2005; 67(3):169-76. PubMed ID: 16089297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia.
    Cools J; Stover EH; Gilliland DG
    Methods Mol Med; 2006; 125():177-87. PubMed ID: 16502585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Murine models of eosinophilic leukemia: a model of FIP1L1-PDGFRα initiated chronic eosinophilic leukemia/systemic mastocytosis.
    Yamada Y; Cancelas JA; Rothenberg ME
    Methods Mol Biol; 2014; 1178():309-20. PubMed ID: 24986627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Murine model of hypereosinophilic syndromes/chronic eosinophilic leukemia.
    Yamada Y; Cancelas JA; Rothenberg ME
    Int Arch Allergy Immunol; 2009; 149 Suppl 1():102-7. PubMed ID: 19494514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Characteristics of cytogenetics and molecular biology in patients with eosinophilia].
    Qu SQ; Ai XF; Li CW; Li QH; Xu ZF; Qin TJ; Zhang Y; Xiao ZJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1216-20. PubMed ID: 23114151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hes1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis.
    Uchida T; Kitaura J; Nakahara F; Togami K; Inoue D; Maehara A; Nishimura K; Kawabata KC; Doki N; Kakihana K; Yoshioka K; Izawa K; Oki T; Sada A; Harada Y; Ohashi K; Katayama Y; Matsui T; Harada H; Kitamura T
    Exp Hematol; 2014 May; 42(5):369-379.e3. PubMed ID: 24486648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.